Q-omics provides the consensus-scored SNORA22C profile across patient tissues and cancer cell-line models. SNORA22C expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, SNORA22C is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, SNORA22C RNA expression shows 11,340 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight DLBC, COAD, and UVM as cancer lineages where SNORA22C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA22C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA22C survival associations across molecular data types. SNORA22C RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA22C RNA expression–survival associations across cancer types. High SNORA22C expression shows unfavorable associations in DLBC, MESO, THCA, ACC, KICH and READ. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for SNORA22C RNA expression.
This table summarizes SNORA22C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA22C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA22C shows lower tumor expression in COAD and higher tumor expression in LUAD. The COAD box plot shows higher SNORA22C RNA expression in normal versus tumor tissue (log2 FC = −0.315, t-test p = .013).
This table shows molecular features associated with SNORA22C in patient tissues and cancer cell lines. In patient samples, SNORA22C shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
